Anoro Ellipta (umeclidinium/vilanterol) / Innoviva, GSK, Sino Biopharm - LARVOL DELTA

Inhaled Bronchodilators to support the use of Beta-Blockers in Chronic Obstructive Pulmonary Disease (COPD). (ANZCTR) - P4 | N=36 | Not yet recruiting | Sponsor: Waikato District Health Board

New P4 trial • Chronic Obstructive Pulmonary Disease • Heart Failure • Immunology • Pulmonary Disease • Respiratory Diseases

SINGLE- VS MULTIPLE-INHALER TRIPLE THERAPY AND EARLY READMISSIONS AFTER ACUTE EXACERBATION OF COPD: A REAL-WORLD HOSPITAL-BASED STUDY (CHEST 2026) - "Collected patient characteristics included age, sex, hospital length of stay (LOS), access to a primary care provider (PCP), cigarette smoking history, forced expiratory volume in one second (FEV1), and use of prophylactic azithromycin...Of these, 176 (60%) were prescribed SITT (131 umeclidinium/vilanterol/fluticasone furoate; 44 glycopyrronium/formoterol/budesonide; and 1 glycopyrronium/ indacaterol/mometasone), and 115 (40%) were prescribed MITT... In this real-world hospital-based study, discharge on SITT was associated with significantly fewer early readmissions for AECOPD compared with MITT. These findings support current guideline recommendations favoring SITT and suggest that simplifying inhaler regimens improves short-term outcomes in high-risk COPD patients. CLINICAL IMPLICATIONS: Prescribing SITT at discharge reduces early AECOPD readmissions and should be prioritized for COPD patients when clinically appropriate."

Clinical • Real-world • Real-world evidence • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

The Efficacy of Umeclidinium/Vilanterol Inhalation Therapy for Preserved Ratio Impaired Spirometry (ChiCTR) - P=N/A | N=146 | Not yet recruiting | Sponsor: THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY; THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY

New trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P4 | N=1032 | Not yet recruiting | Sponsor: Università degli Studi di Ferrara

New P4 trial • Chronic Obstructive Pulmonary Disease • Immunology

Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P4 | N=1032 | Recruiting | Sponsor: Università degli Studi di Ferrara | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P4 | N=1032 | Recruiting | Sponsor: Università degli Studi di Ferrara | Trial completion date: Sep 2020 ➔ Mar 2022 | Trial primary completion date: Jun 2019 ➔ Oct 2021

Trial completion date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

CHHEF: Effect of Dual Bronchodilation With Umeclidinium/Vilanterol on Patients With COPD, Hyperinflation and Heart Failure (clinicaltrials.gov) - P4 | N=60 | Not yet recruiting | Sponsor: Luis Puente Maestu

New P4 trial • Cardiovascular • Chronic Obstructive Pulmonary Disease • Heart Failure • Immunology

CHHEF: Effect of Dual Bronchodilation With Umeclidinium/Vilanterol on Patients With COPD, Hyperinflation and Heart Failure (clinicaltrials.gov) - P4 | N=60 | Not yet recruiting | Sponsor: Luis Puente Maestu | Trial completion date: Oct 2022 ➔ May 2023 | Initiation date: Oct 2020 ➔ May 2021 | Trial primary completion date: Oct 2021 ➔ May 2022

Trial completion date • Trial initiation date • Trial primary completion date • Cardiovascular • Chronic Obstructive Pulmonary Disease • Heart Failure • Immunology • Respiratory Diseases

Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P4 | N=1032 | Recruiting | Sponsor: Università degli Studi di Ferrara | Trial completion date: Mar 2022 ➔ Mar 2023 | Trial primary completion date: Oct 2021 ➔ Oct 2022

Trial completion date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - P4 | N=843 | Terminated | Sponsor: Università degli Studi di Ferrara | Trial completion date: Mar 2023 ➔ Oct 2022 | Recruiting ➔ Terminated; Contract terminated between AIFA and the Sponsor (University of Ferrara)

Trial completion date • Trial termination • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

CHHEF: Effect of Dual Bronchodilation With Umeclidinium/Vilanterol on Patients With COPD, Hyperinflation and Heart Failure (clinicaltrials.gov) - P4 | N=60 | Recruiting | Sponsor: Luis Puente Maestu | Not yet recruiting ➔ Recruiting | Trial completion date: May 2023 ➔ Jun 2024 | Trial primary completion date: May 2022 ➔ Oct 2023

Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • Chronic Obstructive Pulmonary Disease • Heart Failure • Immunology • Pulmonary Disease • Respiratory Diseases

CHHEF: Effect of Dual Bronchodilation With Umeclidinium/Vilanterol on Patients With COPD, Hyperinflation and Heart Failure (clinicaltrials.gov) - P4 | N=60 | Recruiting | Sponsor: Luis Puente Maestu | Trial completion date: Jun 2024 ➔ Dec 2024 | Trial primary completion date: Oct 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Cardiovascular • Chronic Obstructive Pulmonary Disease • Heart Failure • Immunology • Pulmonary Disease • Respiratory Diseases

CHHEF: Effect of dual bronchodilation with umeclidinium/vilanterol on patients with COPD, hyperinflation and heart failure (clinicaltrialsregister.eu) - P4 | N=60 | Recruiting | Sponsor: Hospital General Universitario Gregorio Maranon | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Chronic Obstructive Pulmonary Disease • Heart Failure • Immunology • Pulmonary Disease • Respiratory Diseases

CHHEF: Effect of Dual Bronchodilation With Umeclidinium/Vilanterol on Patients With COPD, Hyperinflation and Heart Failure (clinicaltrials.gov) - P4 | N=60 | Completed | Sponsor: Luis Puente Maestu | Recruiting ➔ Completed | Trial completion date: Dec 2024 ➔ May 2026 | Trial primary completion date: Dec 2024 ➔ May 2026

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Chronic Obstructive Pulmonary Disease • Heart Failure • Immunology • Pulmonary Disease • Respiratory Diseases

The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD (clinicaltrials.gov) - P3 | N=50 | Not yet recruiting | Sponsor: Mahidol University

New P3 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD (clinicaltrials.gov) - P3 | N=50 | Recruiting | Sponsor: Mahidol University | Not yet recruiting ➔ Recruiting | Initiation date: Jun 2024 ➔ Oct 2024

Enrollment open • Trial initiation date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Late Breaking Abstract - Phase IV, single-center, double-blind, randomized, placebo-controlled, crossover clinical trial designed to evaluate the effect of double bronchodilation with umeclidinium/vilanterol in patients with COPD, hyperinflation, and heart failure. (ERS 2026) - "Significant amelioration of lung hyperinflation and dyspnea and meaningful improvements in exercise parameters were also noted. umeclidinium/vilanterol significantly improves cardiac function during exercise in patients with COPD and left ventricular dysfunction Funded: by an unconditional grant by GSK, SEPAR and Neumomadrid"

Clinical • Late-breaking abstract • P4 data • Cardiovascular • Chronic Obstructive Pulmonary Disease • Congestive Heart Failure • Heart Failure • Immunology • Respiratory Diseases

Comparative efficacy of once-daily LAMA/LABA combinations versus tiotropium on constant-work-rate cycle endurance in COPD: a randomized crossover pilot study (COMPETE) (ERS 2026) - "Four treatments were administered in a randomized order (28 days each, 7-day washout): tiotropium/olodaterol, umeclidinium/vilanterol, indacaterol/glycopyrronium, and tiotropium. We demonstrate that head-to-head CWRCE method can be a useful test for assessing the effect of individual medications and their combinations on exercise tolerance. The high interpatient variability highlights the potential for personalized bronchodilator selection based on CPET, justifying further study in larger cohorts."

Clinical • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Trends in the Use and Costs of Medications for Respiratory Management Included in the 2022 Benefit Plan of the Colombia Health System. (PubMed, Drugs Real World Outcomes) - "After the 2022 Benefit Plan update for respiratory conditions such as asthma and chronic obstructive pulmonary disease, increases in the dispensing and direct pharmaceutical costs of the newly included therapies were observed. These temporal changes suggest modifications in prescribing and dispensing patterns, potentially reflecting greater access to recommended first-line therapies, although causal attributions to the Benefit Plan update cannot be established, given the descriptive nature of this study."

Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Efficacy and safety of TQC3403 in patients with chronic obstructive pulmonary disease (COPD): a multicenter, randomized, open-label, phase 3 equivalence trial. (PubMed, J Thorac Dis) - P=N/A | "This study aimed to evaluate the clinical equivalence between TQC3403 [the first generic umeclidinium/vilanterol (UMEC/VI) dry powder inhaler (DPI)] and ANORO®...TQC3403 demonstrated clinical equivalence to ANORO® with respect to efficacy, safety, and tolerability in patients with COPD, supporting its clinical use as an effective and well-tolerated alternative for this population. The clinical research was registered at Chinese Clinical Trial Register (Ref: ChiCTR2600120078)."

Journal • P3 data • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Comparative Real-World Effectiveness of Fixed-Dose Triple Therapy Regimens in COPD: A Retrospective Cohort Study. (PubMed, J Clin Med) - "We compared real-world clinical outcomes among adults with COPD receiving fluticasone furoate/vilanterol/umeclidinium (FF/VI/UMEC) or budesonide/glycopyrrolate/formoterol (BUD/GLY/FOR)... In this large propensity score-matched real-world cohort study, patients receiving BUD/GLY/FOR experienced lower rates of COPD exacerbations and acute respiratory failure than those receiving FF/VI/UMEC. Because of the retrospective observational nature of the analysis, these findings should be considered hypothesis-generating and require confirmation in prospective comparative effectiveness studies."

Journal • Real-world evidence • Retrospective data • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

GSK is expanding its partnership with Chia Tai Tianqing Pharmaceutical Group…by granting the company China commercialization rights for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol; FF/UMEC/VI) and Anoro Ellipta (umeclidinium/vilanterol; UMEC/VI) (AllSci Corp) - "The agreement extends the companies’ May 2026 collaboration around the hepatitis B candidate bepirovirsen into respiratory medicine, creating a multi-product partnership spanning two therapeutic areas. Trelegy and Anoro generated combined global sales of GBP 3.54 billion (approximately USD 4.5 billion) in 2025. Financial terms were not disclosed. Under the agreement, CTTQ will purchase finished product from GSK and book China sales revenue, following the same commercialization and supply model used in the earlier bepirovirsen collaboration."

Licensing / partnership • Chronic Obstructive Pulmonary Disease • Respiratory Diseases

Effect of once-daily ICS/LAMA/LABA triple therapy versus ICS/LABA on respiratory symptoms (E-RS: Asthma): Analysis of the phase IIIA CAPTAIN trial. (PubMed, J Allergy Clin Immunol Glob) - "Addition of the long-acting muscarinic antagonist umeclidinium (UMEC) to the inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) combination fluticasone furoate/vilanterol (FF/VI) improved lung function in adults with uncontrolled moderate to severe asthma in the CAPTAIN (Clinical study of Asthma Patients receiving Triple therapy through A single INhaler) study; however, the impact on symptoms requires further investigation...The CAPTAIN study was a phase IIIA, randomized, controlled, 24- to 52-week study of patients with uncontrolled moderate to severe asthma despite ICS/LABA receiving once-daily single-inhaler FF/VI (100/25 or 200/25 μg) or FF/UMEC/VI (100/31.25/25, 100/62.5/25, 200/31.25/25, or 200/62.5/25 μg)...Similar trends were observed irrespective of type 2 status. Patients with symptomatic asthma may benefit from optimized treatment interventions, such as adding a long-acting muscarinic antagonist to ICS/LABA."

Journal • P1/2 data • P3 data • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery (clinicaltrials.gov) - P3 | N=204 | Active, not recruiting | Sponsor: Samsung Medical Center | Recruiting ➔ Active, not recruiting | Trial completion date: Apr 2024 ➔ Sep 2026 | Trial primary completion date: Nov 2023 ➔ Apr 2026

Enrollment closed • Trial completion date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor

Breztri Aerosphere for asthma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases